title: New-onset diabetes after transplantation: assessment of risk factors and clinical outcomes.
abstract: BACKGROUND
  New-onset diabetes after transplantation (NODAT) is a serious complicatin of kidney transplantation (KT) with adverse impacts on graft and patient survivals. This study aims assess potential risk factors for development of NODAT and compare clinical outcomes of KT recipients with versus without NODAT.
  
  
  METHODS
  We retrospectively evaluated 648 patients who underwent KT between 2005 and 2009. From the 83 (12.8%) subjects who developed NODAT, we selected 47 for comparison with controls free of diabetes.
  
  
  RESULTS
  The diagnosis of NODAT was made at 4.3 ± 8.5 months after transplantation in 47 patients, including 76.6% males, with an overall mean age of 54.5 ± 10.8 years. Patients with NODAT presented higher pretransplantation fasting plasma glucose levels (P < .001) as well as cyclosporine and tacrolimus trough levels (P = .003 and P < .001, respectively). On multivariate analysis, higher pretransplantation fasting plasma glucose and higher tacrolimus, but not cyclosporine concentrations were independent predictors of NODAT. No differences were found for other potential risk factors. Upon follow-up at 6, 12, 24, 36, 48, and 60 months, renal function (estimated Glomerular Filtration Rate using Modification of Diet in Renal Disease), 24 hour proteinuria and proportions of patients with hypertension were similar between groups. Patients with NODAT showed comparable numbers of hospitalizations and infections, as well as acute rejection episodes and acute cardiovascular events as their counterparts. Event-free survival (loss of graft function/death with functioning graft) was similar between the groups (P = .418; K-M).
  
  
  CONCLUSIONS
  In our population, higher pretransplantation fasting plasma glucose levels and higher tacrolimus concentrations were independent predictors of NODAT. During a mean follow-up of 3 years, NODAT was not associated with worse clinical outcomes.
authors.affiliation: Department of Nephrology, Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal. patriciacotovio@gmail.com
authors.forename: P
authors.initials: P
authors.lastname: Cotovio
authors.forename: M
authors.initials: M
authors.lastname: Neves
authors.forename: L
authors.initials: L
authors.lastname: Rodrigues
authors.forename: R
authors.initials: R
authors.lastname: Alves
authors.forename: M
authors.initials: M
authors.lastname: Bastos
authors.forename: C
authors.initials: C
authors.lastname: Baptista
authors.forename: F
authors.initials: F
authors.lastname: Macário
authors.forename: A
authors.initials: A
authors.lastname: Mota
mesh_terms: D000328:Adult; D000368:Aged; D001786:Blood Glucose / Q000032:analysis; D016572:Cyclosporine / Q000493:pharmacokinetics; D003920:Diabetes Mellitus / Q000209:etiology*; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000493:pharmacokinetics; D016030:Kidney Transplantation; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D012307:Risk Factors; D016559:Tacrolimus / Q000493:pharmacokinetics; D016896:Treatment Outcome
chemical_list: D001786:Blood Glucose; D007166:Immunosuppressive Agents; D016572:Cyclosporine; D016559:Tacrolimus